Halia Therapeutics Continued Support to Utah's Industry Community Recognized by First Place at the Utah Business Innovation Awards
LEHI, Utah, Oct. 31, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that the company has been awarded first place in the Medical & Health: MedTech category of the Utah Business Innovation Awards, a recognition of breakthrough innovations that are impacting a broad spectrum of markets and industries within its local community. In addition to this esteemed recognition, and further demonstrating the company's impact on Utah, Dr. David J. Bearss, President and CEO of Halia Therapeutics, has also been appointed as a member of the Board of Directors for BioUtah, Utah's trade association serving the state's life sciences community.
- "Halia is incredibly honored to be recognized as a leading innovator by the medical and health industry of Utah alongside other pioneering companies," said Dr. Bearss.
- "In partnership with Foley & Lardner, the Innovation Awards pay tribute to the innovative spirit permeating Utah companies and the talented people working to alleviate complex problems with elegant solutions.
- Utah Business is proud to recognize Halia Therapeutics as a leading innovator in the Medical & Health: MedTech industry category," said Mekenna Malan, Editor of Utah Business.
- "We are eager to observe the company's progress in its therapeutic development to address chronic diseases."